Resverlogix Corp. (RVX) Fundamentals

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
SHARE INFORMATION
Market Cap$ 64,743,881
Shares Outstanding251,532,405
Float234,937,770
Percent Float94.35%
Short Interest325,770.00
Short Percent Float100.0%
Short Interest Ratio3.4156
Short Interest Date2022-07-31
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 0
Latest Fiscal EPS$ -0.13
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions1
Institutional Holdings Date2022-07-31
Institutional Bought Previous 3 Months-
Institutional Holdings Percent0.0%
Institutional Sold Previous 3 Months-
Insider Holdings Date-
Insider Bought Previous 3 Months-
Insider Holdings Percent0.0
Insider Sold Previous 3 Months-
Insider Shares Owned14,077,158
TRADING INFO
52 Week High$ 0.82
52 Week Low$ 0.205
52 Week High Change$ -58.73
21 Day Moving Average$ 0.270238
21 Day Extended Moving Average$ 0.276095
50 Day Moving Average$ 0.2564
50 Day Extended Moving Average$ 0.281067
200 Day Moving Average$ 0.4438
200 Day Extended Moving Average$ 0.431411
10 Day Average Volume50,338
20 Day Average Volume52,665
30 Day Average Volume62,097
50 Day Average Volume76,451
Alpha0.007595
Beta0.342329
Standard Deviation0.268787
R20.002973
7 Day Price Change$ -0.05
7 Day Percent Change-16.13%
21 Day Price Change$ 0.025
21 Day Percent Change10.64%
30 Day Price Change$ 0.03
30 Day Percent Change13.04%
Month to Date Price Change$ -0.03
Month to Date Percent Change-10.34%
Quarter to Date Price Change$ 0.01
Quarter to Date Percent Change4.0%
180 Day Price Change$ -0.47
180 Day Percent Change-64.38%
200 Day Price Change$ -0.29
200 Day Percent Change-52.73%
Year to Date Price Change$ -0.25
Year to Date Percent Change-49.02%

Resverlogix Corp. (RVX) Key Ratios

PROFITABILITY
EBIT Margin0.0%
EBITDA Margin0.0%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin0.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 0
Revenue Per Share$ 0.00
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book-0.82
Total Debt To Equity0.00
Int Coverage-25.50
Current Ratio0.20
Leverage Ratio-0.20
Quick Ratio0.00
Long Term Debt To Capital0.00
VALUATION MEASURES
PE Ratio-1.80
Enterprise Value$ 70,709,319
Price to Sales0.00
Price to Free Cash-11.30
PE High Last 5 Years88.00
Price To Book0.00
Price To Cash Flow0.00
PE Low Last 5 Years-2.10
Price to Tangible Book-0.82
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-266.86
Return on Equity55.56
Return on Capital0.00

Resverlogix Corp. (RVX) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorKPMG LLP
CEODonald J. McCaffrey
Emplyoees22
Last AuditUE
CIK0001372821
IndustryBiotechnology
SectorHealthcare
NAICSBiological Product (except Diagnostic) Manufacturing(325414)
CONTACT INFO
Address4820 Richard Road S.W
Suite 300
Calgary, AB T3E 6L1
Websitehttps://www.resverlogix.com
Facsimile+1 403 256-8495
Telephone+1 403 254-9252
Emailsarah@resverlogix.com


Your Recent History
TSX
RVX
Resverlogi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.